[go: up one dir, main page]

MX2017004950A - Composiciones y metodos para tratar el insomnio. - Google Patents

Composiciones y metodos para tratar el insomnio.

Info

Publication number
MX2017004950A
MX2017004950A MX2017004950A MX2017004950A MX2017004950A MX 2017004950 A MX2017004950 A MX 2017004950A MX 2017004950 A MX2017004950 A MX 2017004950A MX 2017004950 A MX2017004950 A MX 2017004950A MX 2017004950 A MX2017004950 A MX 2017004950A
Authority
MX
Mexico
Prior art keywords
compositions
methods
treating insomnia
insomnia
dimethylpyrimidin
Prior art date
Application number
MX2017004950A
Other languages
English (en)
Other versions
MX376164B (es
Inventor
Moline Margaret
Pastino Gina
Akimoto Yurie
Zaima Yasuhiro
Suzuki Nobuya
Yoshida Nobuo
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2017004950A publication Critical patent/MX2017004950A/es
Publication of MX376164B publication Critical patent/MX376164B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

En la presente invención, se ha descubierto que un compuesto tal como (1R,2S)-2-(((2,4-dimetilpirimidin-5-il)oxi)metil)-2-(3-fluoro fenil)-N-(5-fluoropiridin-2-il)ciclopropanocarboxamida es un antagonista potente de los receptores de orexina y puede ser útil en el tratamiento de trastornos del sueño tales como el insomnio, así como también para otros usos terapéuticos.
MX2017004950A 2014-10-23 2015-10-21 Composiciones y metodos para tratar el insomnio. MX376164B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462067443P 2014-10-23 2014-10-23
PCT/JP2015/080304 WO2016063995A1 (en) 2014-10-23 2015-10-21 Compositions and methods for treating insomnia

Publications (2)

Publication Number Publication Date
MX2017004950A true MX2017004950A (es) 2018-01-16
MX376164B MX376164B (es) 2025-03-07

Family

ID=55761025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004950A MX376164B (es) 2014-10-23 2015-10-21 Composiciones y metodos para tratar el insomnio.

Country Status (14)

Country Link
US (3) US10188652B2 (es)
EP (1) EP3209298B1 (es)
JP (1) JP6659681B2 (es)
KR (1) KR102444608B1 (es)
CN (1) CN107810006B (es)
AU (1) AU2015336463B2 (es)
BR (1) BR112017007063A2 (es)
CA (1) CA2964504C (es)
ES (1) ES2843952T3 (es)
IL (1) IL251759B (es)
MX (1) MX376164B (es)
RU (1) RU2703297C2 (es)
SG (2) SG10202007759RA (es)
WO (1) WO2016063995A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107810006B (zh) 2014-10-23 2021-03-30 卫材R&D管理有限公司 用于治疗失眠的组合物
CN109640998A (zh) * 2016-05-12 2019-04-16 卫材研究发展管理有限公司 治疗昼夜节律性睡眠障碍的方法
CN116172869A (zh) * 2016-08-10 2023-05-30 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
WO2019024845A1 (zh) * 2017-08-01 2019-02-07 苏州科睿思制药有限公司 一种食欲素受体拮抗剂的晶型及其制备方法和用途
CN113660934A (zh) 2018-11-21 2021-11-16 特默罗制药股份有限公司 罗非昔布的纯化形式、制备方法和用途
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
WO2020264201A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
CN114502167A (zh) * 2019-09-13 2022-05-13 卫材R&D管理有限公司 用于治疗失眠的药物组合物
MX2022003018A (es) * 2019-09-13 2022-06-14 Takeda Pharmaceuticals Co Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia.
US20230051268A1 (en) * 2019-12-20 2023-02-16 Eisai R&D Management Co., Ltd. Use of lemborexant for treating insomnia
CA3164198A1 (en) * 2020-01-16 2021-07-22 Eisai R&D Management Co., Ltd. Drug substance of lemborexant and medicinal composition comprising same
EP4138822A1 (en) 2020-04-19 2023-03-01 Idorsia Pharmaceuticals Ltd Medical use of daridorexant
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
TW202425995A (zh) 2022-09-23 2024-07-01 日商衛材R&D企管股份有限公司 減少與神經退化疾病相關的神經退化的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06328057A (ja) 1993-05-26 1994-11-29 Sanyo Electric Co Ltd 厨芥処理装置
EP0828751A4 (en) 1995-05-05 1999-01-20 Human Genome Sciences Inc HUMAN NEUROPEPTIDE RECEPTOR
US6001963A (en) 1996-12-17 1999-12-14 Smithkline Beecham Corporation Ligands of the neuropeptide receptor HFGAN72
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
WO2005118548A1 (en) 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
JP2008513434A (ja) 2004-09-23 2008-05-01 ファイザー・プロダクツ・インク トロンボポイエチン受容体アゴニスト
JP2006328057A (ja) 2005-04-25 2006-12-07 Eisai R & D Management Co Ltd 抗不安薬及びそのスクリーニング方法
AU2007226203A1 (en) 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
WO2007129188A1 (en) 2006-05-10 2007-11-15 Pfizer Japan Inc. Cyclopropanecarboxamide compound
PE20081368A1 (es) 2006-09-11 2008-11-19 Glaxo Group Ltd Derivados de azabiciclo[4.1.0]heptano como inhibidores de la recaptacion de serotonina, dopamina y norepinefrina
TW200823227A (en) 2006-09-29 2008-06-01 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CL2007003827A1 (es) 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
CN101796018A (zh) 2007-09-21 2010-08-04 塞诺菲-安万特股份有限公司 (环丙基苯基)苯基草酰胺类化合物、其生产方法以及作为药物的用途
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
JP5735010B2 (ja) * 2010-02-15 2015-06-17 コーニンクレッカ フィリップス エヌ ヴェ 制御チャネル干渉の軽減
RU2571414C2 (ru) * 2010-09-22 2015-12-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Циклопропановые соединения
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
CN107810006B (zh) 2014-10-23 2021-03-30 卫材R&D管理有限公司 用于治疗失眠的组合物

Also Published As

Publication number Publication date
SG11201703064WA (en) 2017-05-30
US10702529B2 (en) 2020-07-07
MX376164B (es) 2025-03-07
US20190201399A1 (en) 2019-07-04
JP6659681B2 (ja) 2020-03-04
IL251759B (en) 2021-01-31
CN107810006B (zh) 2021-03-30
AU2015336463A1 (en) 2017-05-04
SG10202007759RA (en) 2020-09-29
US10188652B2 (en) 2019-01-29
KR20170068478A (ko) 2017-06-19
CN107810006A (zh) 2018-03-16
ES2843952T3 (es) 2021-07-21
RU2017112308A3 (es) 2019-05-08
WO2016063995A1 (en) 2016-04-28
US20200268754A1 (en) 2020-08-27
IL251759A0 (en) 2017-06-29
US11026944B2 (en) 2021-06-08
KR102444608B1 (ko) 2022-09-20
CA2964504C (en) 2022-08-23
EP3209298A1 (en) 2017-08-30
RU2703297C2 (ru) 2019-10-16
BR112017007063A2 (pt) 2018-02-14
US20170252342A1 (en) 2017-09-07
EP3209298A4 (en) 2018-06-20
RU2017112308A (ru) 2018-11-26
JP2017531683A (ja) 2017-10-26
CA2964504A1 (en) 2016-04-28
EP3209298B1 (en) 2020-12-02
AU2015336463B2 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
MX2017004950A (es) Composiciones y metodos para tratar el insomnio.
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
NZ710270A (en) Pyridone amides as modulators of sodium channels
PH12017500583B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2018006223A (es) Moduladores de ror-gamma.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
NZ710111A (en) Quinoline and quinoxaline amides as modulators of sodium channels
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
IN2014DN10386A (es)
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
MX2015012741A (es) Palbociclib deuterado.
PH12016501624A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
SG10201907291QA (en) Monomethylfumarate prodrug compositions
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
MY191337A (en) Compositions for the treatment of hypertension and/or fibrosis
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
MY182818A (en) Compositions for the treatment of fibrosis and fibrosis-related conditions
EA201491522A1 (ru) Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина
GB201115977D0 (en) Neurodevelopmental disorders
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen

Legal Events

Date Code Title Description
FG Grant or registration